We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus.
- Authors
Daneshpazhooh, Maryam; Tavakolpour, Soheil; Salehi Farid, Ali; Ebadi, Mehrnoosh; Nili, Ali; Rashidian, Mohammad; Mahmoudi, Hamidreza
- Abstract
The patient did not develop any new lesions during the next 3 months; she was in complete remission on minimal therapy 5 months after biosimilar RTX injection (prednisolone 7.5 mg/day). In addition to the development or reactivation of infections, rare adverse events such as neutropenia and pemphigus worsening after RTX therapy have been reported.3,5,6 There was a probable association with AGEP following RTX in both cases (based on Naranjo scale scores of 7 for both). Dear Editor, Acute generalized exanthematous pustulosis (AGEP) is a rare drug reaction characterized by widespread, sterile pustular lesions throughout the skin.1 AGEP following biologic drugs such as etanercept and tocilizumab have been reported.2 The Food and Drug Administration (FDA) recently approved rituximab (RTX) as a treatment for adult patients with moderate to severe pemphigus vulgaris (PV).3 Here, we report two patients with pemphigus developing AGEP following biosimilar RTX administration.
- Subjects
DRUG eruptions; PEMPHIGUS; RITUXIMAB; PHYSICIANS; PEMPHIGUS vulgaris; MYOCARDIAL ischemia
- Publication
International Journal of Dermatology, 2022, Vol 61, Issue 1, pe14
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.15706